X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=761148
https://endpts.com/fda-shoots-down-spectrums-neutropenia-drug-citing-manufacturing-issues/
https://endpts.com/fda-shoots-down-spectrums-neutropenia-drug-citing-manufacturing-issues/
https://www.businesswire.com/news/home/20210226005034/en/Spectrum-Pharmaceuticals-Announces-Poster-Presentation-at-Upcoming-Miami-Breast-Cancer-Conference
https://www.reuters.com/article/us-spectrum-pharma-fda/fda-delays-decision-on-spectrum-pharmas-drug-candidate-due-to-travel-curbs-idUSKBN27B1CP
https://www.businesswire.com/news/home/20200622005163/en/Spectrum-Pharmaceuticals-Presents-Day-Dosing-Data-ROLONTIS%C2%AE
https://www.biospace.com/article/releases/spectrum-pharmaceuticals-to-present-preclinical-rolontis-eflapegrastim-same-day-dosing-data-at-aacr-virtual-annual-meeting-ii/
https://www.fiercebiotech.com/biotech/spectrum-pharma-nabs-five-prime-gilead-veteran-as-new-clinical-lead
https://www.biospace.com/article/releases/spectrum-pharmaceuticals-initiates-same-day-dosing-clinical-trial-for-rolontis-eflapegrastim-/
https://www.businesswire.com/news/home/20191024005849/en/Spectrum-Pharmaceuticals-Announces-Submission-U.S.-Food-Drug/?feedref=JjAwJuNHiystnCoBq_hl-WFAllVCLJFCqzlmaJ8DKHU4plfPZtlGYRDUHCSmgbii6XkLWuQZD-HgGRnjQvCyg3iCfEFIaJW7-otp9V1XQiK2eHTJy3ZqOEt7kKgLu20J
https://medcitynews.com/2019/01/spectrum-pharmaceuticals-sells-marketed-drugs-to-aurobindo-subsidiary-for-up-to-300m/?rf=1
https://www.businesswire.com/news/home/20181227005058/en/Spectrum-Pharmaceuticals-Announces-Submission-Biologics-License-Application
http://markets.businessinsider.com/news/stocks/spectrum-pharmaceuticals-presents-advance-phase-3-rolontis-eflapegrastim-data-at-mascc-2018-and-announces-the-phase-3-recover-study-met-the-primary-endpoint-1027330410
https://www.businesswire.com/news/home/20180205005261/en/Spectrum-Pharmaceuticals-Announces-ROLONTIS%E2%84%A2-eflapegrastim-Met-Primary/?feedref=JjAwJuNHiystnCoBq_hl-WBlLQO14j4QZPTyX5CYOnwC4VjN53jumZRlnzhBoBxGrCOi9QzgjCezTS3Nw_X6kJUrpSBm-Hav1w-UkdSlG3ltkRSnqzf6ourQGu_UA28CzZCGORvG0LE20YOvo49uqw==
Market Place
Share 
